160 related articles for article (PubMed ID: 35816634)
1. Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E.
Milne P; Abhyankar H; Scull B; Singh P; Chakraborty R; Allen CE; Collin M
Blood Adv; 2022 Aug; 6(16):4901-4904. PubMed ID: 35816634
[No Abstract] [Full Text] [Related]
2. BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.
Zeng K; Ohshima K; Liu Y; Zhang W; Wang L; Fan L; Li M; Li X; Wang Z; Guo S; Yan Q; Guo Y
Hematol Oncol; 2017 Dec; 35(4):845-851. PubMed ID: 27597420
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
[TBL] [Abstract][Full Text] [Related]
4. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.
Sahm F; Capper D; Preusser M; Meyer J; Stenzinger A; Lasitschka F; Berghoff AS; Habel A; Schneider M; Kulozik A; Anagnostopoulos I; Müllauer L; Mechtersheimer G; von Deimling A
Blood; 2012 Sep; 120(12):e28-34. PubMed ID: 22859608
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis.
Varga E; Korom I; Polyánka H; Szabó K; Széll M; Baltás E; Bata-Csörgő Z; Kemény L; Oláh J
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1205-11. PubMed ID: 25351766
[TBL] [Abstract][Full Text] [Related]
6. Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.
Milne P; Bomken S; Slater O; Kumar A; Nelson A; Roy S; Velazquez J; Mankad K; Nicholson J; Yeomanson D; Grundy R; Kamal A; Penn A; Pears J; Millen G; Morland B; Hayden J; Lam J; Madkhali M; MacDonald J; Singh P; Pagan S; Rodriguez-Galindo C; Minkov M; Donadieu J; Picarsic J; Allen C; Bigley V; Collin M
Blood Adv; 2023 May; 7(10):2171-2176. PubMed ID: 36112425
[TBL] [Abstract][Full Text] [Related]
7. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
[TBL] [Abstract][Full Text] [Related]
8. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
[TBL] [Abstract][Full Text] [Related]
9. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
[TBL] [Abstract][Full Text] [Related]
10. Success of Trametinib in the Treatment of Langerhans Cell Histiocytosis With Novel MAPK Pathway Mutations.
Orr K; Hustak S; Beaudoin R; Ray A
J Pediatr Hematol Oncol; 2023 May; 45(4):e534-e538. PubMed ID: 36730444
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.
Acosta-Medina AA; Kemps PG; Zondag TCE; Abeykoon JP; Forma-Borst J; Steenwijk EC; Feijen EAM; Teepen JC; Bennani NN; Schram SM; Shah MV; Davidge-Pitts C; Koster MJ; Ryu JH; Vassallo R; Tobin WO; Young JR; Dasari S; Rech K; Ravindran A; Cleven AHG; Verdijk RM; van Noesel CJM; Balgobind BV; Bouma GJ; Saeed P; Bramer JAM; de Groen RAL; Vermaat JSP; van de Sande MAJ; Smit EF; Langerak AW; van Wezel T; Tonino SH; van den Bos C; van Laar JAM; Go RS; Goyal G; van Halteren AGS
Blood; 2023 Nov; 142(18):1570-1575. PubMed ID: 37595284
[TBL] [Abstract][Full Text] [Related]
12. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
McGinnis LM; Nybakken G; Ma L; Arber DA
Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
[TBL] [Abstract][Full Text] [Related]
13. Genomic Alterations in Langerhans Cell Histiocytosis.
Rollins BJ
Hematol Oncol Clin North Am; 2015 Oct; 29(5):839-51. PubMed ID: 26461146
[TBL] [Abstract][Full Text] [Related]
14. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.
Schwentner R; Kolenová A; Jug G; Schnöller T; Ahlmann M; Meister B; Lehrnbecher T; Minkov M; Hutter C
Pediatr Res; 2019 May; 85(6):856-864. PubMed ID: 30474648
[TBL] [Abstract][Full Text] [Related]
16. BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review.
A Al Hamad M; Albisher HM; Al Saeed WR; Almumtin AT; Allabbad FM; A Shawarby M
BMC Cancer; 2019 Feb; 19(1):170. PubMed ID: 30795755
[TBL] [Abstract][Full Text] [Related]
17. [Langerhans cell histiocytosis of the stomach with BRAF-V600E-mutation: case report and review of the literature].
Sarbia M; Mauerer R; Bettstetter M; Funk A
Z Gastroenterol; 2015 Apr; 53(4):302-5. PubMed ID: 25860580
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of BRAF
Carrere X; Pinto N; Gene Olaciregui N; Galluzzo L; Rossetti E; Celis Passini V; Salvador Marcos N; Chantada G; Braier J; Lavarino C; Felizzia G
Pediatr Blood Cancer; 2021 Jul; 68(7):e29115. PubMed ID: 33991404
[TBL] [Abstract][Full Text] [Related]
19. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
20. Absence of FLT3 and JAK2 (V617F) mutations in Langerhans cell histiocytosis.
Abedalthagafi M; Guo H; Hartmann DP; Ozdemirli M
Leuk Res; 2009 Sep; 33(9):e173-4. PubMed ID: 19395028
[No Abstract] [Full Text] [Related]
[Next] [New Search]
